S-1: a promising new oral fluoropyrimidine derivative

The fluoropyrimidine anticancer agent 5-fluorouracil (5-FU) is active in a wide range of solid tumors, particularly gastric, colorectal, and head and neck cancers. Whilst infusional 5-FU is associated with higher response rates and a favorable safety profile compared with the classical i.v. bolus ad...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Expert opinion on investigational drugs 2009-03, Vol.18 (3), p.335-348
Hauptverfasser:	Saif, Muhammad Wasif, Syrigos, Kostas N, Katirtzoglou, Nikos A
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Animals Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - metabolism Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical Trials as Topic dihydrouracil dehydrogenase (NADP) Drug Combinations Drug Evaluation, Preclinical fluorouracil Humans Neoplasms - drug therapy Neoplasms - pathology Oxonic Acid - administration & dosage Oxonic Acid - metabolism Oxonic Acid - pharmacology Oxonic Acid - therapeutic use S-1 Tegafur - administration & dosage Tegafur - metabolism Tegafur - pharmacology Tegafur - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!